Prognostic Significance of HER2 Positivity in Endometrium Cancer.

IF 2 4区医学 Q3 ONCOLOGY Oncology Research and Treatment Pub Date : 2024-11-29 DOI:10.1159/000542900

Serhat Sekmek, Dogan Bayram, Irfan Karahan, Ismet Seven, Perihan Perkin, Kamil Hakan Muftuoglu, Oznur Bal, Bulent Yalcin, Dogan Uncu, Efnan Algin

{"title":"Prognostic Significance of HER2 Positivity in Endometrium Cancer.","authors":"Serhat Sekmek, Dogan Bayram, Irfan Karahan, Ismet Seven, Perihan Perkin, Kamil Hakan Muftuoglu, Oznur Bal, Bulent Yalcin, Dogan Uncu, Efnan Algin","doi":"10.1159/000542900","DOIUrl":null,"url":null,"abstract":"Introduction: Endometrium cancer is the most common gynecological malignancy in developed countries. In this study, we aimed to investigate the effect of HER2 positivity on prognosis in endometrial cancer.Methods: In our study, patients admitted to our clinic with a diagnosis of endometrial cancer between September 2019 and December 2023 were retrospectively evaluated. Human epidermal growth factor receptor 2 (HER2) immunohistochemistry was performed in 121 patients. HER2-low group (HER2 score: 0 and 1) and HER2-high group (HER2 score: 2 and 3) were defined according to the HER2 immunohistochemistry score in the pathology, and patients were compared accordingly.Results: We observed that 97 (80.2%) of the patients were in the HER2-low group, while 24 (19.8%) were in the HER2-high group. In the OS analysis, age (p = 0.381), menopausal status (p = 0.511), ECOG performance status (p = 0.087), histological type of tumor (p = 0.727), pathological grade (p = 0.206), serum LDH (p = 0.091), and albumin (p = 0.315) levels did not affect the prognosis. Patients with lower FIGO stage (p = 0.003) and HER2-high patients (p = 0.040) had better survival outcomes. Multivariable analysis showed that FIGO stage (p = 0.004) and HER2 status (p = 0.040) were independent risk factors affecting survival in endometrial cancer.Conclusion: As a result of our study, it was observed that FIGO stage and HER2 status were independent risk factors affecting OS in endometrial cancer patients. HER2-high group had a better prognosis than HER2-low group.","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"1-6"},"PeriodicalIF":2.0000,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000542900","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Endometrium cancer is the most common gynecological malignancy in developed countries. In this study, we aimed to investigate the effect of HER2 positivity on prognosis in endometrial cancer.

Methods: In our study, patients admitted to our clinic with a diagnosis of endometrial cancer between September 2019 and December 2023 were retrospectively evaluated. Human epidermal growth factor receptor 2 (HER2) immunohistochemistry was performed in 121 patients. HER2-low group (HER2 score: 0 and 1) and HER2-high group (HER2 score: 2 and 3) were defined according to the HER2 immunohistochemistry score in the pathology, and patients were compared accordingly.

Results: We observed that 97 (80.2%) of the patients were in the HER2-low group, while 24 (19.8%) were in the HER2-high group. In the OS analysis, age (p = 0.381), menopausal status (p = 0.511), ECOG performance status (p = 0.087), histological type of tumor (p = 0.727), pathological grade (p = 0.206), serum LDH (p = 0.091), and albumin (p = 0.315) levels did not affect the prognosis. Patients with lower FIGO stage (p = 0.003) and HER2-high patients (p = 0.040) had better survival outcomes. Multivariable analysis showed that FIGO stage (p = 0.004) and HER2 status (p = 0.040) were independent risk factors affecting survival in endometrial cancer.

Conclusion: As a result of our study, it was observed that FIGO stage and HER2 status were independent risk factors affecting OS in endometrial cancer patients. HER2-high group had a better prognosis than HER2-low group.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

HER2阳性在子宫内膜癌中的预后意义。

子宫内膜癌是发达国家最常见的妇科恶性肿瘤。在本研究中，我们旨在探讨HER2阳性对子宫内膜癌预后的影响。方法：在我们的研究中，回顾性评估2019年9月至2023年12月期间因子宫内膜癌入院的患者。121例患者行人表皮生长因子受体2 （HER2）免疫组化。根据病理中HER2免疫组化评分定义HER2低组（HER2评分：0分和1分）和HER2高组（HER2评分：2分和3分），并对患者进行比较。结果：her2低组97例（80.2%），高组24例（19.8%）。在OS分析中，年龄（p = 0.381）、绝经状态（p = 0.511）、ECOG表现状态（p = 0.087）、肿瘤组织学类型（p = 0.727）、病理分级（p = 0.206）、血清LDH （p = 0.091）和白蛋白（p = 0.315）水平对预后无影响。FIGO分期较低的患者（p = 0.003）和her2分期较高的患者（p = 0.040）有较好的生存结局。多因素分析显示FIGO分期（p = 0.004）和HER-2状态（p = 0.040）是影响子宫内膜癌患者生存的独立危险因素。结论：我们的研究发现FIGO分期和HER2状态是影响子宫内膜癌患者OS的独立危险因素。her2高组预后优于her2低组。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Oncology Research and Treatment ONCOLOGY-

CiteScore

3.20

自引率

0.00%

发文量

期刊介绍： With the first issue in 2014, the journal ''Onkologie'' has changed its title to ''Oncology Research and Treatment''. By this change, publisher and editor set the scene for the further development of this interdisciplinary journal. The English title makes it clear that the articles are published in English – a logical step for the journal, which is listed in all relevant international databases. For excellent manuscripts, a ''Fast Track'' was introduced: The review is carried out within 2 weeks; after acceptance the papers are published online within 14 days and immediately released as ''Editor’s Choice'' to provide the authors with maximum visibility of their results. Interesting case reports are published in the section ''Novel Insights from Clinical Practice'' which clearly highlights the scientific advances which the report presents.